DesignationRef.Download
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2015;2(4):269-39636759
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2016;4:262-37915997
ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2015;2(2):128-1356640
THE ALZHEIMER’S PREVENTION CLINIC AT WEILL CORNELL MEDICAL COLLEGE / NEW YORK - PRESBYTERIAN HOSPITAL: RISK STRATIFICATION AND PERSONALIZED EARLY INTERVENTION J Prev Alz Dis 2015;2(4):254-2666106
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORKJ Prev Alz Dis 2016;3(2):114-1205398
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020J Prev Alz Dis 2020;7(S1):S55-S1194728
VITAMIN D AND DEMENTIAJ Prev Alz Dis 2016;3(1):43-524414
A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) J Prev Alz Dis 2015;2(4):227-2413391
A PERSONALIZED 12-WEEK “BRAIN FITNESS PROGRAM” FOR IMPROVING COGNITIVE FUNCTION AND INCREASING THE VOLUME OF HIPPOCAMPUS IN ELDERLY WITH MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2016;3(3):133-1372912
CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIALJ Prev Alz Dis 2017;4(3):149-1562800
REVERSIBLE AND SPECIES-SPECIFIC DEPIGMENTATION EFFECTS OF AZD3293, A BACE INHIBITOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE, ARE RELATED TO BACE2 INHIBITION AND CONFINED TO EPIDERMIS AND HAIR J Prev Alz Dis 2016;3(4):202-2182678
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER’S DISEASE AND OTHER TAUOPATHIESJ Prev Alz Dis 2017;4(4):236-2412595
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” J Prev Alz Dis 2016;3(4):219-2282508
BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(1):30-422505
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(2):109-1152273
CLINICAL AND ECONOMIC CHARACTERISTICS OF MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: TRANSFORMING FUNCTIONAL SCORES INTO LEVELS OF DEPENDENCEJ Prev Alz Dis 2015;2(2):115-1202243
ETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER’S DISEASE RESEARCHJ Prev Alz Dis 2017;4(2):125-1312193
THE RELATIONSHIP OF OMEGA 3 POLYUNSATURATED FATTY ACIDS IN RED BLOOD CELL MEMBRANES WITH COGNITIVE FUNCTION AND BRAIN STRUCTURE: A REVIEW FOCUSSED ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(1):78-842119
NEFLAMAPIMOD: CLINICAL PHASE 2B-READY ORAL SMALL MOLECULE INHIBITOR OF P38? TO REVERSE SYNAPTIC DYSFUNCTION IN EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):273-2782117
COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMER’S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER J Prev Alz Dis 2016;3(3):164-1722074
BRIDGING THE TRANSLATION GAP: FROM DEMENTIA RISK ASSESSMENT TO ADVICE ON RISK REDUCTIONJ Prev Alz Dis 2015;2(3):189-1981999
POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAMJ Prev Alz Dis 2015;2(3):165-1711840
EVALUATION OF THE NEUROPROTECTIVE POTENTIAL OF N-ACETYLCYSTEINE FOR PREVENTION AND TREATMENT OF COGNITIVE AGING AND DEMENTIAJ Prev Alz Dis 2017;4(3):201-2061808
FROM BRAIN DISEASE TO BRAIN HEALTH: PRIMARY PREVENTION OF ALZHEIMER’S DISEASE AND RELATED DISORDERS IN A HEALTH SYSTEM USING AN ELECTRONIC MEDICAL RECORD-BASED APPROACHJ Prev Alz Dis 2017;4(3):157-1641782
SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL J Prev Alz Dis 2017;4(1):12-151766
THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):242-2461756
CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(3):138-1441689
MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATAJ Prev Alz Dis 2014;1(1):13-221665
ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):157-1631407
B-VITAMIN THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIALJ Prev Alz Dis 2017;4(3):174-1821356
‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALSJ Prev Alz Dis 2016;3(4):229-2351348
THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER’S DISEASE. STRATEGY, METHODS AND INITIAL RESULTSJ Prev Alz Dis 2017;4(3):183-1931342
DEPENDENCE LEVELS AS INTERIM CLINICAL MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: 18-MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDYJ Prev Alz Dis 2017;4(2):72-801323
ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE 2020J Prev Alz Dis 2020;7(2):66-671305
PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: EFFICACY IN PATIENTS WITH MORE PRONOUNCED PSYCHOTIC SYMPTOMSJ Prev Alz Dis 2019;6(1):27-331295
THE CASE FOR USING ACTIGRAPHY GENERATED SLEEP AND ACTIVITY ENDPOINTS IN ALZHEIMER’S DISEASE CLINICAL TRIALSJ Prev Alz Dis 2016;3(3):173-1761291
HEALTH LITERACY IN INDIVIDUALS AT RISK FOR ALZHEIMER’S DEMENTIA: A SYSTEMATIC REVIEWJ Prev Alz Dis 2020;7(1):47-551267
RATIONALE AND STRUCTURE FOR A NEW CENTER FOR STUDIES ON PREVENTION OF ALZHEIMER’S DISEASE (STOP-AD)J Prev Alz Dis 2016;3(4):236-2421225
FATTY ACIDS AND ALZHEIMER’S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIALJ Prev Alz Dis 2018;5(3):168-1701192
VITAMIN E SUPPLEMENTATION REDUCES CELLULAR LOSS IN THE BRAIN OF A PREMATURE AGING MOUSE MODELJ Prev Alz Dis 2017;4(4):226-2351171
IDENTIFYING BETTER OUTCOME MEASURES TO IMPROVE TREATMENT OF AGITATION IN DEMENTIA: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2018;5(2):98-1021126
NANOROBOTS THE FUTURE OF NEUROLOGY: A PERSPECTIVE ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):155-1561082
SAFETY AND EFFICACY OF LEMBOREXANT IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE DEMENTIA: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIALJ Prev Alz Dis 2021;1(8):7-181057
WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCEJ Prev Alz Dis 2018;5(3):171-1701016
PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORTJ Prev Alz Dis 2019;6(3):169-1731014
PSYCHOMETRIC PROPERTIES OF THE CLINICAL DEMENTIA RATING – SUM OF BOXES AND OTHER COGNITIVE AND FUNCTIONAL OUTCOMES IN A PRODROMAL ALZHEIMER’S DISEASE POPULATIONJ Prev Alz Dis 2021;2(8):151-1601012
THE FUTURE OF ANTI-AMYLOID TRIALSJ Prev Alz Dis 2020;3(7):146-151985
PIMAVANSERIN: POTENTIAL TREATMENT FOR DEMENTIA-RELATED PSYCHOSISJ Prev Alz Dis 2018;5(4):253-258956
MULTIDOMAIN INTERVENTIONS TO PREVENT COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, AND DEMENTIA: FROM FINGER TO WORLD-WIDE FINGERSJ Prev Alz Dis 2020;7(1):29-36926
INTEGRATED CARE FOR OLDER PEOPLE AND THE IMPLEMENTATION IN THE INSPIRE CARE COHORTJ Prev Alz Dis 2020;7(2):70-74926
NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER’S DISEASE: AN EU/US CTAD TASK FORCE REPORTJ Prev Alz Dis 2020;3(7):152-157922
REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCEJ Prev Alz Dis 2016;3(2):68-74919
APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDYJ Prev Alz Dis 2019;6(4):248-255898
AN ACTION PLAN TO FACE THE CHALLENGE OF DEMENTIA: INTERNATIONAL STATEMENT ON DEMENTIA FROM IAP FOR HEALTHJ Prev Alz Dis 2018;5(3):207-212877
THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0J Prev Alz Dis 2020;7(1):8-13859
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CAREJ Prev Alz Dis 2020;3(7):165-170850
NUTRITION-BASED APPROACHES IN CLINICAL TRIALS TARGETING COGNITIVE FUNCTION: HIGHLIGHTS OF THE CTAD 2020J Prev Alz Dis 2021;2(8):118-122840
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020J Prev Alz Dis 2020;7(S1):S2-S54837
IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUSJ Prev Alz Dis 2019;6(2):78-84793
UTILIZATION OF OBSERVATIONAL DATA AS A PROXY COHORT FOR COMPARISON PURPOSES WITH OPEN-LABEL STUDY RESULTS: AN EXAMPLE FROM ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(2):90-99783
A MISSED OPPORTUNITY FOR DEMENTIA PREVENTION? CURRENT CHALLENGES FOR EARLY DETECTION AND MODERN-DAY SOLUTIONSJ Prev Alz Dis 2020;4(7):291-293774
A TURNING POINT IN ALZHEIMER’S RESEARCH: HARMONIZED RESEARCH STRATEGIES AND NOVEL INVESTMENTS IN PUBLIC HEALTH INFRASTRUCTURE ARE REENERGIZING THE FIELD, AND REKINDLING HOPE FOR THOSE AFFECTED BY ALZHEIMER’S AND RELATED DEMENTIASJ Prev Alz Dis 2019;6(4):214-216772
CAN DIGITAL TECHNOLOGY ADVANCE THE DEVELOPMENT OF TREATMENTS FOR ALZHEIMER’S DISEASE?J Prev Alz Dis 2019;6(4):217-220766
RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIESJ Prev Alz Dis 2020;3(7):158-164762
THE INTERRELATIONSHIP BETWEEN INSULIN-LIKE GROWTH FACTOR 1, APOLIPOPROTEIN E Ε4, LIFESTYLE FACTORS, AND THE AGING BODY AND BRAINJ Prev Alz Dis 2020;4(7):265-273758
CORTICAL Β-AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATIONJ Prev Alz Dis 2020;7(2):128-134679
TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINEJ Prev Alz Dis 2020;3(7):184-194660
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTINGJ Prev Alz Dis 2020;3(7):171-178648
REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGEJ Prev Alz Dis 2020;7(1):56-64644
ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(4):232-236635
CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIALJ Prev Alz Dis 2018;5(3):202-206627
IMPACT OF THE COVID-19 OUTBREAK ON THE CLINICAL AND RESEARCH ACTIVITIES OF MEMORY CLINICS: AN ALZHEIMER’S DISEASE CENTER FACING THE COVID-19 CRISISJ Prev Alz Dis 2020;3(7):197-198626
POLYGENIC RISK SCORE ANALYSIS OF ALZHEIMER’S DISEASE IN CASES WITHOUT APOE4 OR APOE2 ALLELESJ Prev Alz Dis 2019;6(1):16-19624
ESTABLISHING CLINICAL RELEVANCE IN PRECLINICAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(2):85-87603
EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALSJ Prev Alz Dis 2017;4(2):116-124592
PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALSJ Prev Alz Dis 2020;4(7):213-218583
DIET AS A RISK FACTOR FOR COGNITIVE DECLINE IN AFRICAN AMERICANS AND CAUCASIANS WITH A PARENTAL HISTORY OF ALZHEIMER’S DISEASE: A CROSS- SECTIONAL PILOT STUDY DIETARY PATTERNSJ Prev Alz Dis 2019;6(1):50-55582
THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER’S DISEASE DRUG DEVELOPMENT PROGRAMSJ Prev Alz Dis 2020;4(7):288-290580
COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALSJ Prev Alz Dis 2015;2(2):82-84574
SCREENING FOR MILD COGNITIVE IMPAIRMENT: THERE IS THE WILL BUT IS THERE A WAY?J Prev Alz Dis 2020;3(7):144-145570
IMPACT OF ADUHELM APPROVAL ON CARE AND POLICYJ Prev Alz Dis 2021;4(8):396-397569
POSSIBLE ENDPOINTS IN A PRODROMAL ALZHEIMER’S DISEASE TRIALJ Prev Alz Dis 2015;2(2):88-90561
THE ALZHEIMER’S PREVENTION REGISTRY: A LARGE INTERNET-BASED PARTICIPANT RECRUITMENT REGISTRY TO ACCELERATE REFERRALS TO ALZHEIMER’S-FOCUSED STUDIESJ Prev Alz Dis 2020;4(7):242-250556
A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER’S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUPJ Prev Alz Dis 2020;4(7):274-282547
HOW WILL ADUCANUMAB APPROVAL IMPACT AD RESEARCH?J Prev Alz Dis 2021;4(8):391-392545
THE COMPUTERIZED COGNITIVE COMPOSITE (C3) IN A4, AN ALZHEIMER’S DISEASE SECONDARY PREVENTION TRIALJ Prev Alz Dis 2021;1(8):59-67544
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONSJ Prev Alz Dis 2021;4(8):398-410542
TREATABLE VASCULAR RISK AND COGNITIVE PERFORMANCE IN PERSONS AGED 35 YEARS OR OLDER: LONGITUDINAL STUDY OF SIX YEARSJ Prev Alz Dis 2019;6(1):42-49535
APPLICATION OF DIGITAL COGNITIVE BIOMARKERS FOR ALZHEIMER’S DISEASE: IDENTIFYING COGNITIVE PROCESS CHANGES AND IMPENDING COGNITIVE DECLINEJ Prev Alz Dis 2021;2(8):123-126515
TOULOUSE ALZHEIMER’S CLINICAL RESEARCH CENTER RECOVERY AFTER THE COVID-19 CRISIS: TELEMEDICINE AN INNOVATIVE SOLUTION FOR CLINICAL RESEARCH DURING THE CORONAVIRUS PANDEMICJ Prev Alz Dis 2020;4(7):301-304503
EVALUATION OF THE FISCAL COSTS AND CONSEQUENCES OF ALZHEIMER’S DISEASE IN GERMANY: MICROSIMULATION OF PATIENTS’ AND CAREGIVERS’ PATHWAYS499
DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE: CLINICAL PRACTICE IN 2021J Prev Alz Dis 2021;3(8):371-386482
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) PROJECT: AN OVERVIEWJ Prev Alz Dis 2020;4(7):208-212473
NEXT-GENERATION ALZHEIMER’S THERAPEUTICS: LEVERAGING DEEP BIOLOGYJ Prev Alz Dis 2020;3(7):138-139471
NEW HOPE FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;3(8):238-239461
DIGITAL SCREENING FOR COGNITIVE IMPAIRMENT – A PROOF OF CONCEPT STUDYJ Prev Alz Dis 2021;2(8):127-134458
THIRTY-SIX-MONTH AMYLOID POSITRON EMISSION TOMOGRAPHY RESULTS SHOW CONTINUED REDUCTION IN AMYLOID BURDEN WITH SUBCUTANEOUS GANTENERUMABJ Prev Alz Dis 2021;1(8):3-6457
THE US EXPERT PANEL ON THE APPROPRIATE USE RECOMMENDATIONS OF ADUCANUMAB IN CLINICAL PRACTICEJ Prev Alz Dis 2021;4(8):411440
LETTER TO THE EDITOR REFERRING TO AISEN, P.S. AND R. RAMAN, FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020J Prev Alz Dis 2020;4(7):299-300436
THE TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD): EXPERIENCE FROM THE FIRST 3 YEARSJ Prev Alz Dis 2020;4(7):234-241435
CONSEQUENCES OF THE FDA DECISION ON ADUCANUMAB FOR PATIENT CARE AND RESEARCHJ Prev Alz Dis 2021;4(8):393-395433
PUBLIC POLICY SHOULD FOSTER ALZHEIMER’S TREATMENT AVAILABILITY: COMMENT ON THE DRAFT US MEDICARE DECISION TO LIMIT PAYMENT FOR ADUCANUMAB (ADUHELMTM) TO PATIENTS PARTICIPATING IN CLINICAL TRIALSJ Prev Alz Dis 2022;2(9):241-246431
POLYGENIC RISK SCORING IS AN EFFECTIVE APPROACH TO PREDICT THOSE INDIVIDUALS MOST LIKELY TO DECLINE COGNITIVELY DUE TO ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;1(8):78-83415
TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;2(9):197-210411
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONSJ Prev Alz Dis 2021;4(8):412-413407
THE ROLE OF FUTILITY ANALYSES IN AD CLINICAL TRIALSJ Prev Alz Dis 2020;7(1):7398
INTRANASAL INSULIN REDUCES WHITE MATTER HYPERINTENSITY PROGRESSION IN ASSOCIATION WITH IMPROVEMENTS IN COGNITION AND CSF BIOMARKER PROFILES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;3(8):240-248393
THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINEJ Prev Alz Dis 2020;4(7):294-298367
AMYLOID AND APOE STATUS OF SCREENED SUBJECTS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAMJ Prev Alz Dis 2021;2(8):218-223367
AUTHORS RESPONSE TO UMBRICHT D, LETTER TO THE EDITOR REFERRING FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020J Prev Alz Dis 2020;4(7):300364
THE EPIDEMIOLOGY OF ALZHEIMER’S DISEASE MODIFIABLE RISK FACTORS AND PREVENTIONJ Prev Alz Dis 2021;3(8):313-321357
ESTABLISHING A TRIAL READY COHORT TO ACCELERATE ALZHEIMER’S CLINICAL TRIAL ENROLLMENT AND TREATMENTSJ Prev Alz Dis 2020;4(7):202-203334
RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD)J Prev Alz Dis 2020;4(7):219-225334
ACCELERATING PRECLINICAL ALZHEIMER’S CLINICAL TRIALS THROUGH A TRIAL-READY COHORT WITH DIVERSE REPRESENTATIONJ Prev Alz Dis 2020;4(7):204-205329
TRC-PAD: ACCELERATING RECRUITMENT OF AD CLINICAL TRIALS THROUGH INNOVATIVE INFORMATION TECHNOLOGYJ Prev Alz Dis 2020;4(7):226-233315
ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATAJ Prev Alz Dis 2021;3(8):257-262311
LONGITUDINAL COURSE OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE IN A COHORT STUDY: METHODS, BASELINE AND LONGITUDINAL RESULTS OF THE A3C STUDYJ Prev Alz Dis 2021;2(8):199-209271
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCHJ Prev Alz Dis 2020;4(7):206-207262
THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER\'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT)J Prev Alz Dis 2021;4(8):425-435239
DEMENTIA PREVENTION: A GLOBAL CHALLENGE IN URGENT NEED OF SOLUTIONSJ Prev Alz Dis 2022;1(9):1-2229
PLATFORM TRIALS TO EXPEDITE DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2021;3(8):306-312208
DONANEMAB (LY3002813) PHASE 1B STUDY IN ALZHEIMER’S DISEASE: RAPID AND SUSTAINED REDUCTION OF BRAIN AMYLOID MEASURED BY FLORBETAPIR F18 IMAGINGJ Prev Alz Dis 2021;4(8):414-424206
THE INSTITUTE ON METHODS AND PROTOCOLS FOR ADVANCEMENT OF CLINICAL TRIALS IN ADRD (IMPACT-AD): A NOVEL CLINICAL TRIALS TRAINING PROGRAMJ Prev Alz Dis 2021;3(8):286-291191
COMPARATIVE ANALYSIS OF DIFFERENT DEFINITIONS OF AMYLOID-Β POSITIVITY TO DETECT EARLY DOWNSTREAM PATHOPHYSIOLOGICAL ALTERATIONS IN PRECLINICAL ALZHEIMERJ Prev Alz Dis 2021;1(8):68-77189
CAN VIRTUAL SCIENTIFIC CONFERENCES FACILITATE TWOWAY LEARNING BETWEEN DEMENTIA RESEARCHERS AND PARTICIPANTS?J Prev Alz Dis 2021;3(8):387-388187
MAJOR COST DRIVERS IN ASSESSING THE ECONOMIC BURDEN OF ALZHEIMER’S DISEASE: A STRUCTURED, RAPID REVIEWJ Prev Alz Dis 2021;3(8):362-370186
CLINICAL DEVELOPMENT OF ADUCANUMAB, AN ANTI-A? HUMAN MONOCLONAL ANTIBODY BEING INVESTIGATED FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):255-263181
BLOOD DERIVED AMYLOID BIOMARKERS FOR ALZHEIMER’S DISEASE PREVENTIONJ Prev Alz Dis 2022;1(9):12-21179
EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?J Prev Alz Dis 2019;6(3):150177
MECHANISMS UNDERLYING NON-PHARMACOLOGICAL DEMENTIA PREVENTION STRATEGIES: A TRANSLATIONAL PERSPECTIVEJ Prev Alz Dis 2022;1(9):3-11176
ALZHEIMER’S DISEASE RESEARCH IN JAPAN: A SHORT HISTORY, CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTIONJ Prev Alz Dis 2021;4(8):462-464173
THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE: AMYLOID VS. NON-AMYLOID. WHERE DOES CONSENSUS LIE TODAY? AN CTAD TASK FORCE REPORTJ Prev Alz Dis 2022;2(9):231-235170
A UK-WIDE STUDY EMPLOYING NATURAL LANGUAGE PROCESSING TO DETERMINE WHAT MATTERS TO PEOPLE ABOUT BRAIN HEALTH TO IMPROVE DRUG DEVELOPMENT: THE ELECTRONIC PERSON-SPECIFIC OUTCOME MEASURE (EPSOM) PROGRAMMEJ Prev Alz Dis 2021;4(8):448-456168
Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021J Prev Alz Dis 2021;8(S1):S73-S170157
USING DIGITAL TOOLS TO ADVANCE ALZHEIMER’S DRUG TRIALS DURING A PANDEMIC: THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2021;4(8):513-519155
Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021J Prev Alz Dis 2021;8(S1):S1-S72143
MULTIMODAL PREVENTIVE TRIAL FOR ALZHEIMER’S DISEASE: MIND-ADMINI PILOT TRIAL STUDY DESIGN AND PROGRESSJ Prev Alz Dis 2022;1(9):30-39139
COMPARATIVE EFFICACY, SAFETY, TOLERABILITY, AND EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF DEMENTIA-RELATED PSYCHOSIS (DRP): A SYSTEMATIC LITERATURE REVIEWJ Prev Alz Dis 2021;4(8):520-533135
DIGITAL THERAPEUTICS FOR MCI AND ALZHEIMER’S DISEASE: A REGULATORY PERSPECTIVE - HIGHLIGHTS FROM THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE (CTAD)J Prev Alz Dis 2022;2(9):236-240125
DEVELOPING DISEASE-MODIFYING TREATMENTS IN ALZHEIMER’S DISEASE – A PERSPECTIVE FROM ROCHE AND GENENTECHJ Prev Alz Dis 2017;4(4):264-272123
WHERE DO WE GO FROM HERE?J Prev Alz Dis 2022;2(9):188-189123
DETECTION AND MANAGEMENT OF AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS WITH ALZHEIMER’S DISEASE TREATED WITH ANTI-AMYLOID BETA THERAPYJ Prev Alz Dis 2022;2(9):211-220116
EVIDENCE-BASED TOOLS FOR DIETARY ASSESSMENTS IN NUTRITION EPIDEMIOLOGY STUDIES FOR DEMENTIA PREVENTIONJ Prev Alz Dis 2022;1(9):49-53115
WHAT MATTERS TO PATIENTS WITH ALZHEIMER’S DISEASE AND THEIR CARE PARTNERS? IMPLICATIONS FOR UNDERSTANDING THE VALUE OF FUTURE INTERVENTIONSJ Prev Alz Dis 2022;3(9):550-555115
THE EFFECT OF MULTIDOMAIN INTERVENTIONS ON GLOBAL COGNITION, SYMPTOMS OF DEPRESSION AND APATHY – A POOLED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALSJ Prev Alz Dis 2022;1(9):96-103113
ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS UPDATEJ Prev Alz Dis 2022;2(9):221-230110
MESENCHYMAL STEM CELLS MODULATE SIRT1/MIR-134/ GSK3Β SIGNALING PATHWAY IN A RAT MODEL OF ALZHEIMER\'S DISEASEJ Prev Alz Dis 2022;3(9):458-468109
LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;1(9):178-183108
ASSOCIATIONS OF CARDIOVASCULAR AND NONCARDIOVASCULAR COMORBIDITIES WITH DEMENTIA RISK IN PATIENTS WITH DIABETES: RESULTS FROM A LARGE UK COHORT STUDYJ Prev Alz Dis 2022;1(9):86-91106
DECREASED GRAY–WHITE MATTER CONTRAST OF [11C]-PIB UPTAKE IN COGNITIVELY UNIMPAIRED SUBJECTS WITH SEVERE OBSTRUCTIVE SLEEP APNEAJ Prev Alz Dis 2022;3(9):499-506102
CLINICAL TRIAL ENDPOINTS AND THEIR CLINICAL MEANINGFULNESS IN EARLY STAGES OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;3(9):507-522101
EDITORIAL: THE DAWN OF A NEW ERA OF ALZHEIMER’S RESEARCH AND DRUG DEVELOPMENTJ Prev Alz Dis 2022;3(9):385-386100
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2017;4(4):282-42899
THE ‘ADUCANUMAB STORY’: WILL THE LAST CHAPTER SPELL THE END OF THE ‘AMYLOID HYPOTHESIS’ OR MARK A NEW BEGINNING?J Prev Alz Dis 2022;2(9):190-19299
SITE READINESS FRAMEWORK TO IMPROVE HEALTH SYSTEM PREPAREDNESS FOR A POTENTIAL NEW ALZHEIMER’S DISEASE TREATMENT PARADIGMJ Prev Alz Dis 2022;3(9):542-54996
THE FUTURE OF AD CLINICAL TRIALS WITH THE ADVENT OF ANTI-AMYLOID THERAPIES: AN CTAD TASK FORCE REPORTJ Prev Alz Dis 2022;3(9):393-39995
LIVING ENVIRONMENT, BUILT ENVIRONMENT AND COGNITIVE FUNCTION AMONG OLDER CHINESE ADULTS: RESULTS FROM A CROSS-SECTIONAL STUDYJ Prev Alz Dis 2022;1(9):126-13594
VALIDITY OF ONLINE VERSUS IN-CLINIC SELF-REPORTED EVERYDAY COGNITION SCALEJ Prev Alz Dis 2022;2(9):269-27693
UNSUPERVISED PERFORMANCE OF THE COGSTATE BRIEF BATTERY IN THE BRAIN HEALTH REGISTRY: IMPLICATIONS FOR DETECTING COGNITIVE DECLINEJ Prev Alz Dis 2022;2(9):262-26891
ADUCANUMAB TRIALS EMERGE BUT DON’T ENGAGEJ Prev Alz Dis 2022;2(9):193-19689
LOW AMINO ACID SCORE OF BREAKFAST IS ASSOCIATED WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER JAPANESE ADULTS: A COMMUNITY-BASED LONGITUDINAL STUDYJ Prev Alz Dis 2022;1(9):151-15788
COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):164-16886
A POLYMORPHISM CLUSTER AT THE 2Q12 LOCUS MAY PREDICT RESPONSE TO PIROMELATINE IN PATIENTS WITH MILD ALZHEIMER\'S DISEASEJ Prev Alz Dis 2022;2(9):255-26186
SEX-DRIVEN DIFFERENCES IN THE EFFECTIVENESS OF INDIVIDUALIZED CLINICAL MANAGEMENT OF ALZHEIMER’S DISEASE RISK86
DEVELOPMENT REVIEW OF THE BACE1 INHIBITOR LANABECESTAT (AZD3293/LY3314814)J Prev Alz Dis 2017;4(4):247-25485
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2018;5(S1):S1-S19685
TACKLING A MAJOR DEFICIENCY OF DIVERSITY IN ALZHEIMER’S DISEASE THERAPEUTIC TRIALS: AN CTAD TASK FORCE REPORTJ Prev Alz Dis 2022;3(9):388-39284
EDITORIAL: TAU BASED THERAPEUTICS: ALTERNATIVE APPROACHES IN THE WAR ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(3):151-15282
THE 2018 REVISED FDA GUIDANCE FOR EARLY ALZHEIMER’S DISEASE: ESTABLISHING THE MEANINGFULNESS OF TREATMENT EFFECTSJ Prev Alz Dis 2019;6(4):223-22781
THE SCOTTISH BRAIN HEALTH SERVICE MODEL: RATIONALE AND SCIENTIFIC BASIS FOR A NATIONAL CARE PATHWAY OF BRAIN HEALTH SERVICES IN SCOTLANDJ Prev Alz Dis 2022;2(9):348-35881
WHAT WE LEARN FROM THE CTAD 2018 (CLINICAL TRIALS ALZHEIMER’S DISEASE)J Prev Alz Dis 2018;5(4):214-21580
TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER’S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDYJ Prev Alz Dis 2019;6(3):192-19778
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2014;1(3):214-29675
EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE?J Prev Alz Dis 2019;6(3):153-15475
A CONFORMATIONAL VARIANT OF P53 (U-P53AZ) AS BLOODBASED BIOMARKER FOR THE PREDICTION OF THE ONSET OF SYMPTOMATIC ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;3(9):469-47975
AMYLOID-RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN A COGNITIVELY UNIMPAIRED POPULATION WITH AND WITHOUT CEREBRAL AMYLOID73
EDITORIAL: BLOOD TESTS FOR ALZHEIMER’S DISEASE AND RELATED DISORDERSJ Prev Alz Dis 2019;6(3):155-15670
DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER’S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER’S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB)J Prev Alz Dis 2018;5(1):15-2067
ORAL TAU AGGREGATION INHIBITOR FOR ALZHEIMER’S DISEASE: DESIGN, PROGRESS AND BASIS FOR SELECTION OF THE 16 MG/DAY DOSE IN A PHASE 3, RANDOMIZED, PLACEBOCONTROLLED TRIAL OF HYDROMETHYLTHIONINE MESYLATE66
BIOMARKER AND CLINICAL TRIAL DESIGN SUPPORT FOR DISEASE-MODIFYING THERAPIES: REPORT OF A SURVEY OF THE EU/US: ALZHEIMER’S DISEASE TASK FORCEJ Prev Alz Dis 2018;5(2):103-10964
EDITORIAL: THE CLINICAL TRIALS ALZHEIMER’S DISEASE (CTAD) MEETING IN SAN FRANCISCO, FALL 2022, WILL BE A VERY EXCITING EVENT!J Prev Alz Dis 2022;3(9):38759
TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALSJ Prev Alz Dis 2018;5(1):31-3558
PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2015;2(3):184-18857
IN VIVO DETECTION OF CHANGES RELATED TO CORTICAL COLUMNAR ORGANIZATION AND NEUROINFLAMMATION ACROSS THE AD CONTINUUM56
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):180-18154
DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(1):8-1452
SEX MODERATES THE ASSOCIATION BETWEEN FRAILTY AND MILD BEHAVIORAL IMPAIRMENT52
THE ROAD AHEAD TO CURE ALZHEIMER\'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONSJ Prev Alz Dis 2014;1(3):181-20249
A KETO-MEDIET APPROACH WITH COCONUT SUBSTITUTION AND EXERCISE MAY DELAY THE ONSET OF ALZHEIMER’S DISEASE AMONG MIDDLE-AGED J Prev Alz Dis 2017;4(1):51-5749
ADVANCING ALZHEIMER’S DISEASE TREATMENT: LESSONS FROM CTAD 2018J Prev Alz Dis 2019;6(3):198-20349
CONTINUING PROGRESS IN ALZHEIMER’S DISEASE TRIALS: CAUSE FOR OPTIMISMJ Prev Alz Dis 2017;4(4):211-21248
COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER’S DISEASE LIQUID BIOPSYJ Prev Alz Dis 2019;6(3):182-18448
OVERSIMPLIFICATION OF DEMENTIA RISK REDUCTION MESSAGING IS A THREAT TO KNOWLEDGE TRANSLATION IN DEMENTIA PREVENTION RESEARCHJ Prev Alz Dis 2018;5(1):2-447
PLASMA BIOMARKER FOR ALZHEIMER’S DISEASE: ARE WE READY NOW FOR CLINICAL PRACTICE AND DRUG TRIALS?J Prev Alz Dis 2018;5(3):158-15947
ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: THE ROAD AHEADJ Prev Alz Dis 2015;2(2):78-7946
MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL POPULATIONJ Prev Alz Dis 2019;6(3):185-19146
IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVEDJ Prev Alz Dis 2014;1(1):40-4545
ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDYJ Prev Alz Dis 2019;6(2):85-8945
E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS J Prev Alz Dis 2014;1(2):110-11643
LONGITUDINAL TRAJECTORIES OF CLINICAL DECLINE IN AMYLOID POSITIVE AND NEGATIVE POPULATIONSJ Prev Alz Dis 2016;3(2):92-10043
GLOBAL ALZHEIMER’S PLATFORM TRIAL READY COHORTS FOR THE PREVENTION OF ALZHEIMER’S DEMENTIA J Prev Alz Dis 2016;3(4):185-18743
COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ?J Prev Alz Dis 2019;6(3):174-17643
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEPJ Prev Alz Dis 2019;6(3):17943
COGNITIVE DIGITAL BIOMARKERS FROM AUTOMATED TRANSCRIPTION OF SPOKEN LANGUAGE43
DRUG DEVELOPMENT IN AD: POINT OF VIEW FROM THE INDUSTRYJ Prev Alz Dis 2015;2(4):216-21841
ELECSYS CEREBROSPINAL FLUID ASSAYS ACCURATELY DISTINGUISH ALZHEIMER’S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATIONJ Prev Alz Dis 2022;3(9):491-49841
UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(3):168-17539
ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER’S DISEASE TRIALSJ Prev Alz Dis 2015;2(1):2-339
RESULTS FROM A PHASE II STUDY TO ASSESS THE CLINICAL AND IMMUNOLOGICAL ACTIVITY OF AFFITOPE® AD02 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(2):103-11439
A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF THE EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY, SAFETY AND AMYLOID IMAGING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):192-20139
RECRUITMENT OF AT-RISK PARTICIPANTS FOR CLINICAL TRIALS: A MAJOR PARADIGM SHIFT FOR ALZHEIMER’S DISEASE PREVENTIONJ Prev Alz Dis 2017;4(4):213-21439
THE ROAD AHEAD TO CURE AND PREVENT ALZHEIMER’S DISEASE: IMPLEMENTING PREVENTION INTO PRIMARY CAREJ Prev Alz Dis 2015;2(3):199-21138
THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) FINDINGS FROM THE EXPEDITION3 TRIALJ Prev Alz Dis 2018;5(2):134-13638
PREVENTION: HOW THE PARADIGM IS SHIFTINGJ Prev Alz Dis 2014;1(1):51-5537
COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALSJ Prev Alz Dis 2019;6(3):177-17837
EDITORIAL: JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE (JPAD): BUILDING A “FLEET” AGAINST ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(1):2-336
PRIMARY PREVENTION OF DEMENTIA: THE FUTURE OF POPULATION-BASED MULTIDOMAIN LIFESTYLE INTERVENTIONSJ Prev Alz Dis 2018;5(1):5-736
EDITORIAL : DEMENTIA PREVENTION STRATEGIES – BEYOND THE RANDOMIZED CONTROLLED TRIAL?J Prev Alz Dis 2014;1(2):62-6433
INTERVENTIONS TO PREVENT COGNITIVE DECLINE AND DEMENTIA IN ADULTS WITHOUT COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEWJ Prev Alz Dis 2015;2(1):38-4533
NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGESJ Prev Alz Dis 2015;2(3):155-15633
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):243-25933
BEYOND THE CONTROVERSY ON Aß BLOOD-BASED BIOMARKERSJ Prev Alz Dis 2015;2(1):51-5532
TRIAL DESIGN FOR THE EVALUATION OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: CONSIDERATIONS AND RECOMMENDATIONSJ Prev Alz Dis 2015;2(3):163-16432
METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALESJ Prev Alz Dis 2015;2(2):91-10232
VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDYJ Prev Alz Dis 2016;3(2):75-8432
FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLSJ Prev Alz Dis 2017;4(2):100-10832
GETTING MORE CLINICALLY MEANINGFUL MEASURES OF FUNCTIONAL IMPAIRMENT FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(2):67-6832
HEALTHYBRAINS.ORG: FROM REGISTRY TO RANDOMIZATIONJ Prev Alz Dis 2016;3(3):123-12631
AT A CROSSROADS: A PERSPECTIVE ON DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE IN 2016 J Prev Alz Dis 2016;3(4):181-18431
PROSPECTIVE EVALUATION OF COGNITIVE HEALTH AND RELATED FACTORS IN ELDERLY AT RISK FOR DEVELOPING ALZHEIMER’S DEMENTIA: A LONGITUDINAL COHORT STUDYJ Prev Alz Dis 2019;6(4):256-26631
EDITORIAL : THE BRAINHEALTHREGISTRY.ORG: USING THE INTERNET FOR IDENTIFICATION, ASSESSMENT, SCREENING, RECRUITMENT, AND LONGITUDINAL MONITORING OF SUBJECTS FOR NEUROSCIENCE AND ALZHEIMER’S DISEASE STUJ Prev Alz Dis 2014;1(2):59-6130
PRIMARY PREVENTION OF DEMENTIA: AN EPIDEMIOLOGICAL POINT OF VIEWJ Prev Alz Dis 2016;3(3):160-16330
CTAD 2016 abstract: EXPEDITION3: A PHASE 3 TRIAL OF SOLANEZUMAB IN MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE30
EFFECTS OF OMEGA-3 FATTY ACIDS ON RESTING CEREBRAL PERFUSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2018;5(1):26-3030
IS A LARGE-SCALE SCREENING FOR ALZHEIMER’S DISEASE POSSIBLE? YES, IN A FEW YEARSJ Prev Alz Dis 2019;6(4):221-22230
RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(4):228-23130
EDITORIAL : MULTI-DOMAIN PREVENTION FOR A MULTI-FACTORIAL DISEASEJ Prev Alz Dis 2014;1(1):4-529
PHYSICAL ACTIVITY AND ß-AMYLOID BRAIN LEVELS IN HUMANS: A SYSTEMATIC REVIEWJ Prev Alz Dis 2015;2(1):56-6328
COMMENT : A NEW ERA: DISEASE MODIFYING ALZHEIMER DISEASE PREVENTION TRIALS J Prev Alz Dis 2014;1(2):6828
STUDIES OF AGITATION / AGGRESSION IN ALZHEIMER’S DISEASE – SCIENTIFIC AND OPERATIONAL CHALLENGESJ Prev Alz Dis 2015;2(3):157-15928
DIETARY FACTORS AND COGNITIVE DECLINEJ Prev Alz Dis 2016;3(1):53-6428
THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALSJ Prev Alz Dis 2016;3(1):8-1228
LESSONS TO BE LEARNED ABOUT CLINICAL TRIALS IN PRECLINICAL AD FROM ONGOING LONGITUDINAL STUDIESJ Prev Alz Dis 2015;2(4):214-21528
PREVENTION OF ALZHEIMER’S DISEASE IN CHINESE POPULATIONS: STATUS, CHALLENGES AND DIRECTIONSJ Prev Alz Dis 2018;5(2):90-9428
MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASEJ Prev Alz Dis 2018;5(2):110-11928
A LITERATURE REVIEW OF METHODOLOGIES USED IN RANDOMIZED CLINICAL TRIALS OF AGITATION IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):120-13328
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED J Prev Alz Dis 2014;1(1):8-1027
BLOOD-BRAIN BARRIER PERMEABILITY IN AGING AND ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(3):138-14027
AMYLOID AND TAU BIOMARKERS IN CSFJ Prev Alz Dis 2015;2(1):46-5027
INVESTIGATING FUNCTIONAL IMPAIRMENT IN PRECLINICAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(1):4-627
MRI FOR PRE-DEMENTIA TRIALSJ Prev Alz Dis 2016;3(1):5-727
DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):149-15426
CLINICAL APPLICATION OF APOE IN ALZHEIMER’S PREVENTION: A PRECISION MEDICINE APPROACHJ Prev Alz Dis 2018;5(4):245-25226
LONGITUDINAL COMPARISON OF IN CLINIC AND AT HOME ADMINISTRATION OF THE COGSTATE BRIEF BATTERY AND DEMONSTRATED PRACTICE EFFECTS IN THE MAYO CLINIC STUDY OF AGINGJ Prev Alz Dis 2020;7(1):21-2826
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED?J Prev Alz Dis 2014;1(1):6-725
BASELINE SUBJECTIVE MEMORY COMPLAINTS ASSOCIATE WITH INCREASED RISK OF INCIDENT DEMENTIA: THE PREADVISE TRIALJ Prev Alz Dis 2015;2(1):11-1625
IMMUNOTHERAPY OF AD: ALUM DEMAIN?J Prev Alz Dis 2015;2(2):80-8125
REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCHJ Prev Alz Dis 2019;6(1):2-1525
FACTORS ASSOCIATED WITH ALZHEIMER’S DISEASE: AN OVERVIEW OF REVIEWSJ Prev Alz Dis 2019;6(2):121-13425
NEW IPA CRITERIA FOR AGITATION IN COGNITIVE IMPAIRMENTJ Prev Alz Dis 2015;2(3):160-16224
COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIESJ Prev Alz Dis 2017;4(1):3-1124
TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(3):160-16424
IMPACT OF DIETARY FACTORS AND INFLAMMATION ON COGNITION AMONG OLDER ADULTSJ Prev Alz Dis 2015;2(4):220-22623
WEB-BASED SOFTWARE FOR REAL-TIME SIMULATION-ASSISTED TRIAL DESIGN IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(1):20-2323
TEA FOR ALZHEIMER PREVENTIONJ Prev Alz Dis 2015;2(2):136-14123
SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMESJ Prev Alz Dis 2016;3(1):13-1923
BARRIERS FOR PREVENTION AND PRODROMAL AD TRIALSJ Prev Alz Dis 2016;3(2):66-6723
THE VALUE OF PRE-SCREENING IN THE ALZHEIMER’S PREVENTION INITIATIVE (API) AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE TRIALJ Prev Alz Dis 2018;5(1):49-5423
ALZHEIMER’S PREVENTION EDUCATION: IF WE BUILD IT, WILL THEY COME? www.AlzU.orgJ Prev Alz Dis 2014;1(2):91-9822
COMMENT : ALZHEIMER’S DISEASE DRUG DEVELOPMENT: TRIAL-READY COHORTS SHOULD HELPJ Prev Alz Dis 2014;1(2):69-7022
ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA?J Prev Alz Dis 2014;1(3):141-14222
FOREWORD: AD DRUG DEVELOPMENT IS NOT BROKEN: CLINICAL TRIALS IN ALZHEIMER’S DISEASE 2014 CONFERENCE, PHILADELPHIAJ Prev Alz Dis 2014;1(3):212-21322
COGNITIVE REHABILITATION IN ALZHEIMER’S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEWJ Prev Alz Dis 2015;2(2):142-15222
DEMENTIA PREVENTION BY DISEASE-MODIFICATION THROUGH NUTRITIONJ Prev Alz Dis 2017;4(3):138-13922
A NOVEL STUDY PARADIGM FOR LONG-TERM PREVENTION TRIALS IN ALZHEIMER DISEASE: THE PLACEBO GROUP SIMULATION APPROACH (PGSA). APPLICATION TO MCI DATA FROM THE NACC DATABASEJ Prev Alz Dis 2014;1(2):99-10921
DEMENTIA PREVENTION: OPTIMIZING THE USE OF OBSERVATIONAL DATA FOR PERSONAL, CLINICAL, AND PUBLIC HEALTH DECISION-MAKING J Prev Alz Dis 2014;1(2):117-12321
ALZHEIMER’S ASSOCIATION: INITIATIVES & PUBLIC HEALTH PERSPECTIVEJ Prev Alz Dis 2016;3(4):178-18021
ALBUMIN, HEMOGLOBIN, AND THE TRAJECTORY OF COGNITIVE FUNCTION IN COMMUNITY-DWELLING OLDER JAPANESE: A 13-YEAR LONGITUDINAL STUDY J Prev Alz Dis 2017;4(2):93-9921
ADHERENCE TO THE MEDITERRANEAN DIET IS NOT RELATED TO BETA-AMYLOID DEPOSITION: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECTJ Prev Alz Dis 2018;5(2):137-14121
PTI-125 REDUCES BIOMARKERS OF ALZHEIMER’S DISEASE IN PATIENTSJ Prev Alz Dis 2020;4(7):256-26421
COMMENT : E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS FOR STUDY J Prev Alz Dis 2014;1(2):66-6720
A PATIENT-CENTERED ANALYSIS OF ENROLLMENT AND RETENTION IN A RANDOMIZED BEHAVIORAL TRIAL OF TWO COGNITIVE REHABILITATION INTERVENTIONS FOR MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2014;1(3):143-15020
THE HARVARD AUTOMATED PHONE TASK: NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING TESTS FOR EARLY ALZHEIMER’S DISEASE J Prev Alz Dis 2015;2(4):242-25320
GINKGO BILOBA EXTRACT CONSUMPTION AND LONG-TERM OCCURRENCE OF DEATH AND DEMENTIAJ Prev Alz Dis 2017;4(1):16-2020
ARIZONA ALZHEIMER’S REGISTRY: STRATEGY AND OUTCOMES OF A STATEWIDE RESEARCH RECRUITMENT REGISTRY J Prev Alz Dis 2014;1(2):74-7919
COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER’S DISEASE IN ITALY: RESULTS FROM AN OBSERVATIONAL STUDYJ Prev Alz Dis 2018;5(1):55-6419
PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMER’S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDYJ Prev Alz Dis 2019;6(1):34-4119
THINKING ABOUT COGNITIVE FRAILTYJ Prev Alz Dis 2015;2(1):7-1018
ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT)J Prev Alz Dis 2015;2(2):121-12718
A NOVEL EIGENVECTOR-BASED METHOD TO DETECT MILD ALZHEIMER’S DISEASE USING EVENT-RELATED POTENTIALSJ Prev Alz Dis 2016;3(2):101-10418
PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A LONGITUDINAL STUDYJ Prev Alz Dis 2018;5(4):236-24418
DESIGNING TRIALS OF DISEASE MODIFYING AGENTS FOR EARLY AND PRECLINICAL ALZHEIMER’S DISEASE INTERVENTION: WHAT EVIDENCE IS MEANINGFUL TO PATIENTS, PROVIDERS, AND PAYERS?J Prev Alz Dis 2019;6(1):20-2618
AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENTJ Prev Alz Dis 2019;6(1):63-6918
COMMENT: HIGH ALZHEIMER’S DISEASE STUDY COMPLEXITY - LOW SUCCESS RATEJ Prev Alz Dis 2014;1(1):11-1217
AN OPEN-LABEL TRIAL OF YOKUKANSAN ON SLEEP DISTURBANCE IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAJ Prev Alz Dis 2015;2(3):172-17717
NEUROPSYCHOLOGICAL PROFILE OF “COGNITIVE FRAILTY” SUBJECTS IN MAPT STUDYJ Prev Alz Dis 2016;3(3):151-15917
THE PARADOX OF RESEARCH ON DEMENTIA-ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):189-19117
SWINGS AND ROUNDABOUTS IN CNS DRUG BIOMARKERSJ Prev Alz Dis 2017;4(3):134-13517
BRAIN DONATION BY PROXY: ARE THERE PREDICTORS IN NEURODEGENERATIVE DEMENTIA?J Prev Alz Dis 2014;1(3):151-15916
THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ONJ Prev Alz Dis 2014;1(3):176-18016
INTEGRATING INFORMATION FROM FDG - AND AMYLOID PET FOR DETECTING DIFFERENT TYPES OF DEMENTIA IN OLDER PERSONS. A CASE-SERIES STUDYJ Prev Alz Dis 2016;3(3):127-13216
FEMALE SEX AND ALZHEIMER’S RISK: THE MENOPAUSE CONNECTIONJ Prev Alz Dis 2018;5(4):225-23016
REPORT FROM THE FIRST CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) ASIA-CHINA 2018 : BRINGING TOGETHER GLOBAL LEADERSJ Prev Alz Dis 2019;6(2):144-14716
DIETARY FAT INTAKE AND COGNITIVE FUNCTION AMONG OLDER POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSISJ Prev Alz Dis 2019;6(3):204-21116
COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE SUBSCALE: A VALIDATION STUDYJ Prev Alz Dis 2019;6(4):237-24116
ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW PREVENTION CLINICAL TRIAL16
COMMENT : CLINICAL TRIALS FOR ALZHEIMER’S DISEASE TURNED A CORNER IN 2013’ J Prev Alz Dis 2014;1(2):71-7315
COMMUNITY-BASED INTERVENTION FOR PREVENTION OF DEMENTIA IN JAPANJ Prev Alz Dis 2015;2(1):71-7615
AURAPTENE IN THE PEELS OF CITRUS KAWACHIENSIS (KAWACHIBANKAN) CONTRIBUTES TO THE PRESERVATION OF COGNITIVE FUNCTION: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERSJ Prev Alz Dis 2018;5(3):197-20115
DIABETES MELLITUS AND COGNITIVE DECLINE – PREVENTION SHOULD NOT BE DELAYED!J Prev Alz Dis 2018;5(2):95-9715
FEASIBILITY OF USING A WEARABLE BIOSENSOR DEVICE IN PATIENTS AT RISK FOR ALZHEIMER’S DISEASE DEMENTIAJ Prev Alz Dis 2020;7(2):104-11115
MEDITERRANEAN DIET AND MAGNETIC RESONANCE IMAGING-ASSESSED BRAIN ATROPHY IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(1):23-3214
HIPPOCAMPAL ASTROCYTES AND ALZHEIMER’S DISEASE J Prev Alz Dis 2014;1(2):124-12814
JPAD IS MOVING FASTJ Prev Alz Dis 2016;3(1):3-414
ANTIOXIDANTS IN THE DIET AND COGNITIVE FUNCTION: WHICH ROLE FOR THE MEDITERRANEAN LIFE-STYLE?J Prev Alz Dis 2017;4(1):58-6414
CLINICAL EFFECTS OF ORAL TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATIONJ Prev Alz Dis 2017;4(3):136-13714
EPIGALLOCATECHIN 3-GALLATE AS AN INHIBITOR OF TAU PHOSPHORYLATION AND AGGREGATION: A MOLECULAR AND STRUCTURAL INSIGHTJ Prev Alz Dis 2017;4(4):218-22514
WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE?J Prev Alz Dis 2018;5(3):165-16714
INCREASED FUNCTIONAL CONNECTIVITY AFTER LISTENING TO FAVORED MUSIC IN ADULTS WITH ALZHEIMER DEMENTIAJ Prev Alz Dis 2019;6(1):56-6214
IMPLEMENTING A MEMORY CLINIC MODEL TO FACILITATE RECRUITMENT INTO EARLY PHASE CLINICAL TRIALS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(2):135-13814
OVERTREATING ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;2(8):234-23614
THE ROLE OF AΒ IN ALZHEIMER’S DISEASE AS AN EVOLUTIONARY OUTCOME OF OPTIMIZED INNATE IMMUNE DEFENSE14
HIGHER COGNITIVE PERFORMANCE IS PROSPECTIVELY ASSOCIATED WITH HEALTHY DIETARY CHOICES: THE MAINE SYRACUSE LONGITUDINAL STUDYJ Prev Alz Dis 2015;2(1):24-3213
DIABETES MITIGATES THE ROLE OF MEMORY COMPLAINT IN PREDICTING DEMENTIA RISK: RESULTS FROM THE PREVENTION OF ALZHEIMER’S DISEASE WITH VITAMIN E AND SELENIUM STUDYJ Prev Alz Dis 2017;4(3):143-14813
CARE MANAGEMENT TO PROMOTE TREATMENT ADHERENCE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND VASCULAR RISK FACTORS: A DEMONSTRATION PROJECTJ Prev Alz Dis 2018;5(1):36-4113
COGNITIVE FRAILTY AND INCIDENCE OF DEMENTIA IN OLDER PERSONSJ Prev Alz Dis 2018;5(1):42-4813
ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER’S DISEASE IN EXPEDITION 3J Prev Alz Dis 2018;5(3):184-18713
COST-EFFECTIVENESS OF DEMENTIA PREVENTION INTERVENTIONSJ Prev Alz Dis 2021;2(8):210-21713
MEMORY BROUGHT TO MIND. FIVE-YEAR FOLLOW-UP OF CASE FINDING AND INTERVENTION OF DEMENTIA IN A SWEDISH PRIMARY HEALTH CARE DISTRICTJ Prev Alz Dis 2015;2(1):17-2312
IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENTJ Prev Alz Dis 2015;2(1):64-7012
THE EFFECT OF VASCULAR NEUROPATHOLOGY ON LATE-LIFE COGNITION: RESULTS FROM THE SMART PROJECTJ Prev Alz Dis 2016;3(2):85-9112
SHORT-TERM PRACTICE EFFECTS AND AMYLOID DEPOSITION: PROVIDING INFORMATION ABOVE AND BEYOND BASELINE COGNITIONJ Prev Alz Dis 2017;4(2):87-9212
COMBINING GEOSPATIAL ANALYSIS WITH DEMENTIA RISK UTILISING GENERAL PRACTICE DATA: A SYSTEMATIC REVIEWJ Prev Alz Dis 2018;5(1):71-7712
PROSPECTS FOR EFFECTIVE TREATMENT OF THE DEMENTIA-ALZHEIMER SYNDROME: A RENEWED ODYSSEY IN SEARCH OF THE MAGIC ELIXIRJ Prev Alz Dis 2017;4(4):215-21712
ASSESSMENT OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT)J Prev Alz Dis 2018;5(4):216-22412
BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDREDJ Prev Alz Dis 2019;6(2):112-12012
GEROSCIENCE AND THE ROLE OF AGING IN THE ETIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2020;7(1):2-312
DATA-DRIVEN PARTICIPANT RECRUITMENT: FINDINGS FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 3J Prev Alz Dis 2020;7(2):122-12712
A MACHINE LEARNING FRAMEWORK FOR ASSESSMENT OF COGNITIVE AND FUNCTIONAL IMPAIRMENTS IN ALZHEIMER’S DISEASE: DATA PREPROCESSING AND ANALYSISJ Prev Alz Dis 2020;7(2):87-9412
EFFECTIVENESS OF THE OPEN SCREENING PROGRAMS IN RECRUITING SUBJECTS TO PRODROMAL AND MILD ALZHEIMER’S DISEASE CLINICAL TRIALSJ Prev Alz Dis 2020;4(7):251-25512
CURRENT STATE OF SELF-ADMINISTERED BRIEF COMPUTERIZED COGNITIVE ASSESSMENTS FOR DETECTION OF COGNITIVE DISORDERS IN OLDER ADULTS: A SYSTEMATIC REVIEWJ Prev Alz Dis 2021;3(8):267-27612
THE UPS AND DOWNS OF AMYLOID IN ALZHEIMER’SJ Prev Alz Dis 2022;1(9):92-9512
THE TIMECOURSE OF GLOBAL COGNITIVE GAINS FROM SUPERVISED COMPUTER-ASSISTED COGNITIVE TRAINING: A RANDOMISED, ACTIVE-CONTROLLED TRIAL IN ELDERLY WITH MULTIPLE DEMENTIA RISK FACTORSJ Prev Alz Dis 2014;1(1):33-3911
NEW FINDINGS WITH REANALYSIS OF THE DOMINO TRIAL ?J Prev Alz Dis 2015;2(3):21211
ASSESSING THE RELATIONSHIP BETWEEN VITAMIN D STATUS AND IMPAIRMENTS IN COGNITIVE AND PHYSICAL PERFORMANCE IN OLDER ADULTS USING A DUAL TASK PHYSICAL PERFORMANCE TEST J Prev Alz Dis 2017;4(1):29-3611
ASSOCIATIONS OF LONG-TERM TEA CONSUMPTION WITH DEPRESSIVE AND ANXIETY SYMPTOMS IN COMMUNITY-LIVING ELDERLY: FINDINGS FROM THE DIET AND HEALTHY AGING STUDYJ Prev Alz Dis 2018;5(1):21-2511
EFFECTS OF A SIX-MONTH MULTI-INGREDIENT NUTRITION SUPPLEMENT INTERVENTION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, VITAMIN D, RESVERATROL, AND WHEY PROTEIN ON COGNITIVE FUNCTION IN OLDER ADULTS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIALJ Prev Alz Dis 2018;5(3):175-18311
MEDITERRANEAN-DASH INTERVENTION FOR NEURODEGENERATIVE DELAY (MIND) DIET SLOWS COGNITIVE DECLINE AFTER STROKEJ Prev Alz Dis 2019;6(4):267-27311
FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESSJ Prev Alz Dis 2020;3(7):195-19611
CEREAL INTAKE INCREASES AND DAIRY PRODUCTS DECREASE RISK OF COGNITIVE DECLINE AMONG ELDERLY FEMALE JAPANESEJ Prev Alz Dis 2014;1(3):160-16710
THE RELATIONSHIP OF HEMOGLOBIN LEVELS, DELIRIUM AND COGNITIVE STATUS IN HOSPITALIZED GERIATRIC PATIENTS: RESULTS FROM THE CRIME STUDYJ Prev Alz Dis 2015;2(3):178-18310
STIMULUS-LOCKED LATERALIZED READINESS POTENTIAL AND PERFORMANCE: USEFUL MARKERS FOR DIFFERENTIATING BETWEEN AMNESTIC SUBTYPES OF MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2017;4(1):21-2810
SEX AND AGE DIFFERENCES IN THE ASSOCIATION OF BLOOD PRESSURE AND HYPERTENSION WITH COGNITIVE FUNCTION IN THE ELDERLY: THE RANCHO BERNARDO STUDYJ Prev Alz Dis 2017;4(3):165-17310
DEMENTIA: CREATING A KNOWLEDGE-BASED HEALTHCARE PROFESSIONJ Prev Alz Dis 2018;5(1):85-8610
LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLYJ Prev Alz Dis 2018;5(1):8710
DETECTION OF RATER ERRORS ON COGNITIVE INSTRUMENTS IN A CLINICAL TRIAL SETTINGJ Prev Alz Dis 2018;5(3):188-19610
BIFIDOBACTERIUM BREVE A1 SUPPLEMENTATION IMPROVED COGNITIVE DECLINE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: AN OPEN-LABEL, SINGLE-ARM STUDYJ Prev Alz Dis 2019;6(1):70-7510
IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: CURRENT SCENARIO AND FUTURE PERSPECTIVESJ Prev Alz Dis 2021;4(8):534-55110
INTER-SPECIES GLIA DIFFERENCES: IMPLICATIONS FOR SUCCESSFUL TRANSLATION OF TRANSGENIC RODENT ALZHEIMER’S DISEASE MODEL TREATMENT USING BEXAROTENEJ Prev Alz Dis 2014;1(1):46-509
CURCUMIN MICELLES IMPROVE MITOCHONDRIAL FUNCTION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE J Prev Alz Dis 2014;1(2):80-839
MODERATE, REGULAR ALCOHOL CONSUMPTION IS ASSOCIATED WITH HIGHER COGNITIVE FUNCTION IN OLDER COMMUNITY-DWELLING ADULTSJ Prev Alz Dis 2016;3(2):105-1139
COGNITIVE PERFORMANCE DOES NOT LIMIT PHYSICAL ACTIVITY PARTICIPATION IN THE LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS PILOT STUDY (LIFE-P)J Prev Alz Dis 2017;4(1):44-509
OBJECTIVE COGNITIVE IMPAIRMENT AND PROGRESSION TO DEMENTIA IN WOMEN: THE PROSPECTIVE EPIDEMIOLOGICAL RISK FACTOR STUDYJ Prev Alz Dis 2017;4(3):194-2009
EXPANDING THE TOOLKIT FOR STUDIES OF AGINGJ Prev Alz Dis 2017;4(2):69-709
FINANCIAL MANAGEMENT SKILLS IN AGING, MCI AND DEMENTIA: CROSS SECTIONAL RELATIONSHIP TO 18F-FLORBETAPIR PET CORTICAL Β-AMYLOID DEPOSITIONJ Prev Alz Dis 2019;6(4):274-2829
LINKING GEROSCIENCE AND INTEGRATED CARE TO REINFORCE PREVENTIONJ Prev Alz Dis 2020;7(2):68-699
ELEVATED BLOOD HOMOCYSTEINE AND RISK OF ALZHEIMER’S DEMENTIA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON PROSPECTIVE STUDIESJ Prev Alz Dis 2021;3(8):329-3349
PREDICTION OF COGNITIVE DECLINE FOR ENRICHMENT OF ALZHEIMER’S DISEASE CLINICAL TRIALSJ Prev Alz Dis 2022;3(9):400-4099
EFFECT OF PUNICALAGIN AND RESVERATROL ON METHIONINE SULFOXIDE REDUCTASE: A POSSIBLE PROTECTIVE CONTRIBUTION AGAINST ALZHEIMER DISEASEJ Prev Alz Dis 2015;2(1):33-378
MODEST OVERWEIGHT AND HEALTHY DIETARY HABITS REDUCE RISK OF DEMENTIA: A NATIONWIDE SURVEY IN TAIWANJ Prev Alz Dis 2017;4(1):37-438
ACTIVITIES OF DAILY LIVING MEASURED BY THE HARVARD AUTOMATED PHONE TASK TRACK WITH COGNITIVE DECLINE OVER TIME IN NON-DEMENTED ELDERLYJ Prev Alz Dis 2017;4(2):81-868
POTENTIAL UTILITY OF PRACTICE EFFECTS IN PREVENTIVE TRIALSJ Prev Alz Dis 2017;4(3):140-1428
STRONG RELATIONSHIP BETWEEN MALNUTRITION AND COGNITIVE FRAILTY IN THE SINGAPORE LONGITUDINAL AGEING STUDIES (SLAS-1 AND SLAS-2)J Prev Alz Dis 2018;5(2):142-1488
RESPONSES: LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLYJ Prev Alz Dis 2018;5(1):878
CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTSJ Prev Alz Dis 2019;6(2):139-1438
SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER’S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017J Prev Alz Dis 2019;6(2):108-1118
NEUROPSYCHOLOGICAL, PSYCHIATRIC, AND FUNCTIONAL CORRELATES OF CLINICAL TRIAL ENROLLMENTJ Prev Alz Dis 2019;6(4):242-2478
SENSITIVITY OF THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC), PACC5, AND REPEATABLE BATTERY FOR NEUROPSYCHOLOGICAL STATUS (RBANS) TO AMYLOID STATUS IN PRECLINICAL ALZHEIMER’S DISEASE -ATABECESTAT PHASE 2B/3 EARLY CLINICAL TRIALJ Prev Alz Dis 2022;2(9):255-2618
NEUROPROTECTIVE EFFECTS OF A VARIETY OF POMEGRANATE JUICE EXTRACTS (PJE) AGAINST THE EXCITOTOXIN QUINOLINIC ACID IN HUMAN PRIMARY NEURONS J Prev Alz Dis 2014;1(2):84-907
GINKGETIN AMELIORATES NEUROPATHOLOGICAL CHANGES IN APP/PS1 TRANSGENICAL MICE MODELJ Prev Alz Dis 2016;3(1):24-297
EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITYJ Prev Alz Dis 2016;3(4):1887
LETTER TO THE EDITOR: PREVENTING DEMENTIA THROUGH COMMUNITY INVOLVEMENT AND ALTRUISTIC BEHAVIORSJ Prev Alz Dis 2018;5(4):259-2607
GEOGRAPHIC CLUSTERS OF ALZHEIMER’S DISEASE MORTALITY RATES IN THE USA: 2008-2012J Prev Alz Dis 2018;5(4):231-2357
MRI CLINICAL RATINGS AND COGNITIVE FUNCTION IN A CROSS-SECTIONAL POPULATION STUDY OF DEMENTIA: THE CACHE COUNTY MEMORY STUDYJ Prev Alz Dis 2019;6(2):100-1077
SELF-ADMINISTERED COGNITIVE TESTING BY OLDER ADULTS AT-RISK FOR COGNITIVE DECLINEJ Prev Alz Dis 2020;4(7):283-2877
THE EU/US TASK FORCE’S FUTURE FOR ANTI-AMYLOID TRIALS: FAITES VOS JEUXJ Prev Alz Dis 2020;3(7):199-2007
NUTRITION TO PREVENT OR TREAT COGNITIVE IMPAIRMENT IN OLDER ADULTS: A GRADE RECOMMENDATIONJ Prev Alz Dis 2021;1(8):110-1167
PROSPECTIVE ASSOCIATIONS BETWEEN PLASMA AMYLOIDBETA 42/40 AND FRAILTY IN COMMUNITY-DWELLING OLDER ADULTSJ Prev Alz Dis 2021;1(8):41-477
SUGAR IN BEVERAGE AND THE RISK OF INCIDENT DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A PROSPECTIVE COHORT STUDYJ Prev Alz Dis 2021;2(8):188-1937
A WEB-BASED MULTIDOMAIN LIFESTYLE INTERVENTION FOR OLDER ADULTS: THE EMIND RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2021;2(8):142-1507
EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON COGNITIVE IMPAIRMENT AND INFLAMMATION IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMIZED, SINGLE-BLINDED, PLACEBO-CONTROLLED TRIALJ Prev Alz Dis 2021;3(8):249-2567
LETTER TO THE EDITOR: BEYOND FRAILTY IN ALZHEIMER’S DISEASE: SHOULD WE MOVE TO THE CONCEPT OF INTRINSIC CAPACITY?7
EFFECTS OF COMPUTERIZED COGNITIVE TRAINING ON GAIT SPEED IN COMMUNITY DWELLING OLDER ADULTS, A PILOT STUDYJ Prev Alz Dis 2016;3(3):145-1505
DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER’S DISEASE SPECTRUMJ Prev Alz Dis 2020;3(7):179-1835
AN INDUSTRY PERSPECTIVE: FUTURE OF ANTI-AMYLOID TRIALSJ Prev Alz Dis 2020;3(7):142-1435
A IS FOR AMYLOIDJ Prev Alz Dis 2020;3(7):140-1415
A JAPANESE MULTICENTER STUDY ON PET AND OTHER BIOMARKERS FOR SUBJECTS WITH POTENTIAL PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;4(8):495-5025
COHORT-SPECIFIC OPTIMIZATION OF MODELS PREDICTING PRECLINICAL ALZHEIMER’S DISEASE, TO ENHANCE SCREENING PERFORMANCE IN THE MIDDLE OF PRECLINICAL ALZHEIMER’S DISEASE CLINICAL STUDIESJ Prev Alz Dis 2021;4(8):503-5125
DISEASE BURDEN AND ATTRIBUTABLE RISK FACTORS OF ALZHEIMER’S DISEASE AND DEMENTIA IN CHINA FROM 1990 TO 2019J Prev Alz Dis 2022;2(9):306-3145
AGING, SENESCENCE, AND DEMENTIAJ Prev Alz Dis 2022;3(9):523-5315
CLINICAL RESEARCH INVESTIGATING ALZHEIMER’S DISEASE IN CHINA: CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTIONJ Prev Alz Dis 2022;3(9):532-5415
EFFECTS OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2020;7(2):112-1214
SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERSJ Prev Alz Dis 2020;7(1):4-64
IS RELUCTANCE TO SHARE ALZHEIMER’S DISEASE BIOMARKER STATUS WITH A STUDY PARTNER A BARRIER TO PRECLINICAL TRIAL RECRUITMENT?J Prev Alz Dis 2021;1(8):52-584
A NOVEL COMPUTERIZED COGNITIVE STRESS TEST TO DETECT MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2021;2(8):135-1414
ENVIRONMENTAL DISTRACTIONS DURING UNSUPERVISED REMOTE DIGITAL COGNITIVE ASSESSMENTJ Prev Alz Dis 2021;3(8):263-2664
QUANTIFYING RECRUITMENT SOURCE AND PARTICIPANT COMMUNICATION PREFERENCES FOR ALZHEIMER’S DISEASE PREVENTION RESEARCHJ Prev Alz Dis 2021;3(8):299-3054
PERIPHERAL BLOOD BRCA1 METHYLATION POSITIVELY CORRELATES WITH MAJOR ALZHEIMER’S DISEASE RISK FACTORSJ Prev Alz Dis 2021;4(8):477-4824
THE ASSOCIATION BETWEEN PEANUT AND PEANUT BUTTER CONSUMPTION AND COGNITIVE FUNCTION AMONG COMMUNITY-DWELLING OLDER ADULTSJ Prev Alz Dis 2021;4(8):436-4414
NEUROPROTECTIVE EFFECTS OF GUARANA (PAULLINIA CUPANA MART.) AGAINST VINCRISTINE IN VITRO EXPOSUREJ Prev Alz Dis 2018;5(1):65-703
EFFECTS OF RICE WINE LEES ON COGNITIVE FUNCTION IN COMMUNITY-DWELLING PHYSICALLY ACTIVE OLDER ADULTS: A PILOT RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2020;7(2):95-1033
THE PATIENT IN YOUR ALZHEIMER’S DISEASE STUDY MAY BE IN ANOTHER: DUPLICATION AND DECEPTION IN CLINICAL TRIALS OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2020;7(1):43-463
EXPLORING FACTORS THAT CONTRIBUTE TO JOINING AND REGULARLY PRACTICING IN COGNITIVE TRAINING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP QUALITATIVE STUDYJ Prev Alz Dis 2020;7(2):75-813
COMMUNICATING PERSONAL RISK PROFILES OF ALZHEIMER’S DISEASE TO OLDER ADULTS: A PILOT TRIALJ Prev Alz Dis 2022;1(9):144-1503
REPRESENTATION OF RACIAL AND ETHNIC MINORITY POPULATIONS IN DEMENTIA PREVENTION TRIALS: A SYSTEMATIC REVIEWJ Prev Alz Dis 2022;1(9):113-1183
KETONE ESTER EFFECTS ON BIOMARKERS OF BRAIN METABOLISM AND COGNITIVE PERFORMANCE IN COGNITIVELY INTACT ADULTS ≥ 55 YEARS OLD. A STUDY PROTOCOL FOR A DOUBLEBLINDED RANDOMIZED CONTROLLED CLINICAL TRIALJ Prev Alz Dis 2022;1(9):54-663
EDITORIAL : ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA?2
EFFECTS ON COGNITION OF BERRY, POMEGRANATE, GRAPE AND BIOPHENOLS: A GENERAL REVIEW2
INTEGRATING BIOMARKER OUTCOMES INTO CLINICAL TRIALS FOR ALZHEIMER’S DISEASE IN DOWN SYNDROMEJ Prev Alz Dis 2021;1(8):48-512
MENTAL COMPONENT SCORE (MCS) FROM HEALTH-RELATED QUALITY OF LIFE PREDICTS INCIDENCE OF DEMENTIA IN U.S. MALESJ Prev Alz Dis 2021;2(8):169-1742
A SYSTEMATIC REVIEW ON THE FEASIBILITY OF SALIVARY BIOMARKERS FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;1(8):84-912
EXECUTIVE FUNCTION PREDICTS THE VALIDITY OF SUBJECTIVE MEMORY COMPLAINTS IN OLDER ADULTS BEYOND DEMOGRAPHIC, EMOTIONAL, AND CLINICAL FACTORSJ Prev Alz Dis 2021;2(8):161-1682
DOES TEA DRINKING PROMOTE HEALTH OF OLDER ADULTS: EVIDENCE FROM THE CHINA HEALTH AND NUTRITION SURVEYJ Prev Alz Dis 2021;2(8):194-1982
DETERMINANTS OF MEDICAL DIRECT COSTS OF CARE AMONG PATIENTS OF A MEMORY CENTERJ Prev Alz Dis 2021;3(8):351-3612
MAIL AND TELEPHONE OUTREACH FROM ELECTRONIC HEALTH RECORDS FOR RESEARCH PARTICIPATION ON COGNITIVE HEALTH AND AGINGJ Prev Alz Dis 2021;3(8):292-2982
SENOLYTIC THERAPY TO MODULATE THE PROGRESSION OF ALZHEIMER’S DISEASE (STOMP-AD): A PILOT CLINICAL TRIALJ Prev Alz Dis 2022;1(9):22-292
IS “PRE-PRECLINICAL AD” HELPFUL TO THE EU/US CTAD TASK FORCE?J Prev Alz Dis 2022;1(9):1842
ANXIETY AND DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID-Β BURDEN IN COGNITIVELY UNIMPAIRED OLDER ADULTSJ Prev Alz Dis 2022;2(9):286-2962
EFFECTIVENESS OF PHYSICAL EXERCISE ON ALZHEIMER’S DISEASE. A SYSTEMATIC REVIEW2
ASSOCIATIONS OF LATER-LIFE EDUCATION, THE BDNF VAL66MET POLYMORPHISM AND COGNITIVE CHANGE IN OLDER ADULTSJ Prev Alz Dis 2020;7(1):37-421
ASSOCIATION OF VITAMIN D LEVELS WITH INCIDENT ALLCAUSE DEMENTIA IN LONGITUDINAL OBSERVATIONAL STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSISJ Prev Alz Dis 2020;7(1):14-201
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA1
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA1
KNOWLEDGE, ATTITUDE AND PREVENTIVE PRACTICE ON DEMENTIA CARE AMONG PRIMARY HEALTH PROFESSIONALS IN MACAOJ Prev Alz Dis 2020;7(2):83-861
THE EFFECT OF BASELINE PERFORMANCE AND AGE ON COGNITIVE TRAINING IMPROVEMENTS IN OLDER ADULTS: A QUALITATIVE REVIEWJ Prev Alz Dis 2021;1(8):100-1091
PHYSICAL FITNESS AND APOLIPOPROTEIN E GENOTYPE INFLUENCE CORTICAL NETWORKING AND INTELLIGENCE IN ADOLESCENTSJ Prev Alz Dis 2021;1(8):92-991
COMPARATIVE EFFECTIVENESS OF BEHAVIORAL INTERVENTIONS TO PREVENT OR DELAY DEMENTIA: ONEYEAR PARTNER OUTCOMESJ Prev Alz Dis 2021;1(8):33-401
MOLECULAR SUBTYPING OF MILD COGNITIVE IMPAIRMENT BASED ON GENETIC POLYMORPHISM AND GENE EXPRESSIONJ Prev Alz Dis 2021;2(8):224-2331
CHINESE VERSION OF THE BAYLOR PROFOUND MENTAL STATUS EXAMINATION: A BRIEF STAGING MEASURE FOR PATIENTS WITH SEVERE ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;2(8):175-1801
CHILDHOOD SECONDHAND SMOKE EXPOSURE AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE IN ADULTHOOD: A PROSPECTIVE COHORT STUDYJ Prev Alz Dis 2021;3(8):345-3501
DETERMINANTS OF POST-OPERATIVE COGNITIVE DECLINE IN ELDERLY PEOPLEJ Prev Alz Dis 2021;3(8):322-3281
DEVELOPMENT, VALIDATION AND FIELD EVALUATION OF THE SINGAPORE LONGITUDINAL AGEING STUDY (SLAS) RISK INDEX FOR PREDICTION OF MILD COGNITIVE IMPAIRMENT AND DEMENTIAJ Prev Alz Dis 2021;3(8):335-3441
ASSOCIATION OF SUBJECTIVE COGNITIVE DECLINE WITH RISK OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE LONGITUDINAL STUDIESJ Prev Alz Dis 2021;3(8):277-2851
A FAY-HERRIOT MODEL FOR ESTIMATING SUBJECTIVE COGNITIVE DECLINE AMONG MILITARY VETERANSJ Prev Alz Dis 2021;4(8):457-4611
EARLY-ONSET SUBGROUP OF TYPE 2 DIABETES AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A COHORT STUDYJ Prev Alz Dis 2021;4(8):442-4471
DIVERSIFYING RECRUITMENT REGISTRIES: CONSIDERING NEIGHBORHOOD HEALTH METRICSJ Prev Alz Dis 2022;1(9):119-1251
EVALUATION OF MEMANTINE IN AAV-AD RAT: A MODEL OF LATEONSET ALZHEIMER’S DISEASE PREDEMENTIAJ Prev Alz Dis 2022;2(9):338-3471
THE SINGAPORE GERIATRIC INTERVENTION STUDY TO REDUCE COGNITIVE DECLINE AND PHYSICAL FRAILTY (SINGER): STUDY DESIGN AND PROTOCOLJ Prev Alz Dis 2022;1(9):40-481
AT A GLANCE: AN UPDATE ON NEUROIMAGING AND RETINAL IMAGING IN ALZHEIMER’S DISEASE AND RELATED RESEARCHJ Prev Alz Dis 2022;1(9):67-761
STUDY PROTOCOL OF A COMPREHENSIVE ACTIVITY PROMOTIONJ Prev Alz Dis 2022;2(9):376-3841
CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATSJ Prev Alz Dis 2022;3(9):480-4901
EFFECTS OF NON-INVASIVE BRAIN STIMULATION ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2022;3(9):410-4241
LETTER TO THE EDITOR: EARLY-ONSET TYPE 2 DIABETES AND RISK OF DEMENTIAJ Prev Alz Dis 2022;3(9):5611
ALZHEIMER\'S DISEASE PREVENTION HEALTH COACHINGJ Prev Alz Dis 2022;2(9):277-2851
A HIERARCHICAL BAYESIAN LATENT CLASS MODEL FOR THE DIAGNOSTIC PERFORMANCE OF MINI-MENTAL STATE EXAMINATION AND MONTREAL COGNITIVE ASSESSMENT IN SCREENING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE1